Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
05 mai 2017 09h00 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer
07 janv. 2016 09h24 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
20 nov. 2015 08h30 HE
|
Aegerion Pharmaceuticals, Inc.
TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for...
Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety
16 juin 2015 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces First Quarter 2015 Financial Results
04 mai 2015 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
- Company records $59.4 million in total net product sales -
- JUXTAPID® net product sales of $57.3 million in the first quarter of 2015 represents 112% growth over the first quarter of 2014...
Aegerion Pharmaceuticals Observes Rare Disease Day
28 févr. 2015 07h15 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results
26 févr. 2015 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
- Company records $158.4 million in net product sales of JUXTAPID® in 2014, representing 226% growth over 2013 -
- Company generates $17.9 million in positive cash flow from operations in the...
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company Healthcare Conference
25 févr. 2015 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules Approved in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
10 févr. 2014 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
20 janv. 2014 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 20, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...